Page last updated: 2024-12-05

indigotindisulfonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indigo carmine (acid form) : A member of the class of indolones obtained by formal 2,2'-oxidative coupling of two molecules of 3-oxo-2,3-dihydroindole-5-sulfonic acids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3705
CHEMBL ID1091250
CHEBI ID90117
SCHEMBL ID2727226
SCHEMBL ID2732840
SCHEMBL ID5455215
MeSH IDM0515721

Synonyms (54)

Synonym
disodium 5, 5'-indigodisulfonate
sodium 5, 5'-indigodisulfonate
sodium indigo-5, 5'-bisulfonate
1h-indole-5-sulfonic acid, 2-(1, 3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidene)-2,3-dihydro-3-oxo-, disodium salt
(2z)-3-oxo-2-(3-oxo-5-sulfo-indolin-2-ylidene)indoline-5-sulfonic acid
{[.delta.2,2'-biindoline]-5,5'-disulfonic} acid, 3, 3'-dioxo-, disodium salt
5,5'-indigotindisulfonic acid
{[.delta.(sup2,2')biindoline]-5,5'-disulfonic} acid, 3,3'-dioxo-, disodium salt
1h-indole-5-sulfonic acid, 2-(1, 3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidine)-2,3-dihydro-3-oxo-, disodium salt
nsc-8646
NCGC00159432-02
NCGC00159432-03
3,3'-dioxo-2,2'-bis-indolyden-5,5'-disulfonic acid
indigotindisulfonate
indigo carmine acid
blue x
saxon blue
indigotindisulfonic acid
CHEMBL1091250
chebi:90117 ,
(2e)-3-oxo-2-(3-oxo-5-sulfo-1h-indol-2-ylidene)-1h-indole-5-sulfonic acid
dtxsid0044288 ,
tox21_113169
tox21_113170
dtxcid601022746
cas-483-20-5
2-(1,3-dihydro-3-oxo-5-sulpho-2h-indol-2-ylidene)-3-oxoindoline-5-sulphonic acid
einecs 207-593-7
x7oi7jf73p ,
483-20-5
unii-x7oi7jf73p
1h-indole-5-sulfonic acid, 2-(1,3-dihydro-3-oxo-5-sulfo-2h-indol-2-ylidene)-2,3-dihydro-3-oxo-
SCHEMBL2727226
SCHEMBL2732840
SCHEMBL5455215
AKOS024386980
(2e)-3-oxo-2-(3-oxo-5-sulfo-1,3-dihydro-2h-indol-2-ylidene)-2,3-dihydro-1h-indole-5-sulfonic acid
indigo carmine (acid form)
indigo-5,5'-disulfonic acid
indigo carmine free acid
mfcd00005723
(2e)-3-oxo-2-(3-oxo-5-sulfo-1,3-dihydro-2h-indol-2-ylidene)indoline-5-sulfonic acid
DB11577
Q27162327
3,3'-dioxo-[2,2'-biindolinylidene]-5,5'-disulfonic acid
2-(3-hydroxy-5-sulfo-1h-indol-2-yl)-3-oxoindole-5-sulfonic acid
STARBLD0000901
acido indigotindisolfonico
acido indigotindisulffonico
acido indigotindisulfonico
acide indigotindisulfonique
(e)-3,3'-dioxo-1h,1'h,3h,3'h-[2,2'-biindolylidene]-5,5'-disulfonic acid
EN300-26913798
indigo blue, solubl

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.84890.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency11.22020.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
phosphopantetheinyl transferaseBacillus subtilisPotency22.38720.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency24.36160.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.40610.000229.305416,493.5996AID743075; AID743079
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency354.81300.010039.53711,122.0200AID1479
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.31910.000323.4451159.6830AID743065; AID743067
DNA polymerase kappa isoform 1Homo sapiens (human)Potency44.66840.031622.3146100.0000AID588579
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID472449Inhibition of human recombinant C-terminal FLAG-tagged autotaxin expressed in baculovirus-infected Sf9 cells assessed as FS-3 hydrolysis at 10 uM relative to control2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
AID284124Herbicidal activity against Brassica campestris L assessed as inhibition of rape root growth at 10 ug/ml2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach.
AID284122Inhibition of Arabidopsis thaliana AHAS2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach.
AID284123Herbicidal activity against Brassica campestris L assessed as inhibition of rape root growth at 100 ug/ml2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Identification of some novel AHAS inhibitors via molecular docking and virtual screening approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.82 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index38.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]